DDInter9 DDInter1147
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Acalabrutinib may lead to a major life threatening interaction when taken with Idelalisib
Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Acalabrutinib may lead to a major life threatening interaction when taken with Flurbiprofen